Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements and Government Contract (Details)

v3.21.1
Sponsored Research and License Agreements and Government Contract (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2021
Jan. 31, 2021
Feb. 29, 2020
Jan. 31, 2020
Dec. 31, 2019
Oct. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Collaborations                            
Upfront payment received                 $ 125,000,000.0          
Accretion expense                 60,000          
Accounts receivable                 142,195,000         $ 15,973,000
License agreement with unrelated third party                            
Collaborations                            
Proceeds from License Fees Received $ 4,000,000.0                          
One-time fee received from license rights granted $ 4,000,000.0                          
Revenue recognized                 4,000,000          
Specified Development Events                            
Collaborations                            
Contingent payments                 437,500,000          
Specified Regulatory Events                            
Collaborations                            
Contingent payments                 313,700,000          
Specified Product Launch Events                            
Collaborations                            
Contingent payments                 816,000,000.0          
Development and regulatory milestones by non-CNS disease products                            
Collaborations                            
Contingent payments                 330,000,000.0          
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                            
Collaborations                            
Contingent payments                 100,000,000.0          
Development and regulatory milestones by CNS disease products                            
Collaborations                            
Contingent payments                 255,000,000.0          
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                            
Collaborations                            
Contingent payments                 150,000,000.0          
Maximum                            
Collaborations                            
Contingent payments                 1,500,000,000          
Grifols                            
Collaborations                            
Upfront payment received             $ 30,000,000.0              
Contingent payments                 277,500,000          
Revenue, cumulative catch-up       $ 25,000,000.0                    
Deferred revenue                 1,600,000         1,600,000
Revenue, remaining performance obligation                           $ 5,000,000.0
Grifols | Licensed Rights                            
Collaborations                            
Revenue recognized                     $ 39,900,000      
Grifols | Research Services                            
Collaborations                            
Revenue recognized                 0   $ 3,200,000      
Grifols | Commercial Milestones                            
Collaborations                            
Contingent payments             $ 297,500,000              
Revenue recognized                 1,000,000.0          
Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                            
Collaborations                            
Revenue, cumulative catch-up       $ 20,000,000.0                    
Kissei                            
Collaborations                            
Upfront payment received               $ 33,000,000.0            
Contingent payments               $ 147,000,000.0            
Revenue recognized                   $ 0   $ 0    
Revenue, remaining performance obligation                 33,000,000.0          
Lilly                            
Collaborations                            
Deferred revenue                 6,500,000          
fostamatinib                            
Collaborations                            
Government contract   $ 16,500,000                        
Revenue recognized                 3,000,000.0          
Accounts receivable                 1,000,000.0          
Remaining amount of government award expected to be received in succeeding periods                 13,500,000          
fostamatinib | Grifols                            
Collaborations                            
Collaborative payment received     $ 20,000,000.0                      
Markup percentage         30.00%                  
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                            
Collaborations                            
Contingent payments     17,500,000                      
Collaborative payment received     17,500,000                      
fostamatinib | Grifols | Creditable advance royalty payment                            
Collaborations                            
Collaborative payment received     $ 2,500,000                      
fostamatinib | Grifols | Maximum                            
Collaborations                            
Royalty payment as a percentage of net sales                         30.00%  
fostamatinib | Kissei                            
Collaborations                            
Revenue, remaining performance obligation                 $ 1,400,000          
fostamatinib | Medison Pharma | Financing arrangement                            
Collaborations                            
Upfront payment received           $ 5,000,000.0                
fostamatinib | Medison Pharma | Commercial and license agreements                            
Collaborations                            
Upfront payment received           $ 5,000,000.0                
R552                            
Collaborations                            
Company's percentage of development costs                 20.00%          
Financing component liability                 $ 57,900,000          
Financing liability interest accretion discount rate                 6.40%          
Financing liability with accreted interest expense                 $ 58,000,000.0          
Revenue, remaining performance obligation                 67,100,000          
R552 | Maximum                            
Collaborations                            
Funding commitment                 65,000,000.0          
Non-CNS penetrant IP                            
Collaborations                            
Revenue recognized                 60,400,000          
Non-CNS penetrant IP | Licensed Rights                            
Collaborations                            
Revenue, remaining performance obligation                 6,700,000          
CNS penetrant IP                            
Collaborations                            
Revenue recognized                 $ 243,000